tiprankstipranks
Wuxi Biologics (Cayman) Inc. (HK:2269)
:2269
Hong Kong Market
2269
Wuxi Biologics (Cayman)
RESEARCH TOOLSreports
Want to see HK:2269 full AI Analyst Report?

Wuxi Biologics (Cayman) (2269) Income Statement

55 Followers

Wuxi Biologics (Cayman) Income Statement

Last quarter (Q4 2025), Wuxi Biologics (Cayman)'s total revenue was ¥11.64B, an increase of 36.26% from the same quarter last year. In Q4, Wuxi Biologics (Cayman)'s net income was ¥2.53B. See Wuxi Biologics (Cayman)’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
¥ 21.23B¥ 18.68B¥ 17.03B¥ 15.27B¥ 10.29B
Gross Profit
¥ 9.76B¥ 7.65B¥ 6.83B¥ 6.72B¥ 4.83B
Operating Expenses
¥ 3.28B¥ 2.68B¥ 2.38B¥ 2.38B¥ 1.64B
Depreciation and Amortization
¥ 1.70B¥ 1.44B¥ 1.17B¥ 800.67M¥ 481.78M
EBITDA
¥ 8.17B¥ 6.43B¥ 5.50B¥ 6.22B¥ 4.51B
Operating Income
¥ 6.47B¥ 4.97B¥ 4.45B¥ 4.34B¥ 3.19B
Other Income/Expenses
¥ 594.61M¥ -139.41M¥ -276.39M¥ 1.02B¥ 805.01M
Pretax Income
¥ 7.07B¥ 4.83B¥ 4.17B¥ 5.36B¥ 3.99B
Net Income
¥ 4.78B¥ 3.36B¥ 3.40B¥ 4.42B¥ 3.39B
Per Share Metrics
Basic EPS
¥ 1.19¥ 0.82¥ 0.82¥ 1.06¥ 0.81
Diluted EPS
¥ 1.13¥ 0.78¥ 0.77¥ 1.01¥ 0.77
Weighted Average Shares Outstanding
 4.03B 4.08B 4.16B 4.17B 4.40B
Weighted Average Shares Outstanding (Diluted)
 4.18B 4.23B 4.35B 4.38B 4.42B
Currency in CNY

Wuxi Biologics (Cayman) Earnings and Revenue History